Research
Hormonal
Discontinuation of semaglutide treatment leads to significant weight regain, resulting in net weight loss that is substantially lower than the peak loss achieved during treatment.
If you stop taking semaglutide, you will likely regain most of the weight you lost. The net weight loss after stopping is much smaller than the peak loss. Long-term maintenance may require continued treatment.
StrongQualifiesHIGH confidence
Following treatment withdrawal, semaglutide and placebo participants regained 11.6 and 1.9 percentage points of lost weight, respectively, by week 120, resulting in net losses of 5.6% and 0.1% respectively
Why this rating
Based on RCT extension data.
Source
Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs)
Mahvish Anam et al. · Cureus · 2022
DOI 10.7759/cureus.32610
systematic_reviewCited 35×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →